Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
about
Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysisStatistical Methods for Establishing Personalized Treatment Rules in OncologyAnalysis of time to event outcomes in randomized controlled trials by generalized additive modelsMeta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.Targeted survival improvements in clinical trials: are you an absolutist or relativist?Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort studyModeling absolute differences in life expectancy with a censored skew-normal regression approach.On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve.Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancerTargeted temperature management in cardiac arrest: survival evaluated by propensity score matching.Weekday and Survival After Cardiac Surgery-A Swedish Nationwide Cohort Study in 106 473 Patients.Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.Validation of a prognostic index for Huntington's disease.Considerations for Comprehensive Analyses of Sporozoite-Based Controlled Human Malaria Infection Studies.Weighted analysis of composite endpoints with simultaneous inference for flexible weight constraints.Restricted mean survival time over 15 years for patients starting renal replacement therapy.Risk patterns in drug safety study using relative times by accelerated failure time models when proportional hazards assumption is questionable: an illustrative case study of cancer risk of patients on glucose-lowering therapies.Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence.Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients.Estimating restricted mean treatment effects with stacked survival models.The effect of health insurance on childhood cancer survival in the United States.The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.Hip Fracture Surgery and Survival in Centenarians.Prognostic Value of Braden Activity Subscale for Mobility Status in Hospitalized Older Adults.Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises.Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma.Do intra-articular hyaluronic acid injections delay total knee replacement in patients with osteoarthritis - A Cox model analysis.Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.Kidney transplant outcomes from older deceased donors: a paired kidney analysis by the European Renal Association-European Dialysis and Transplant Association Registry.Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.Analysis of restricted mean survival time for length-biased data.Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.Optimal threshold estimator of a prognostic marker by maximizing a time-dependent expected utility function for a patient-centered stratified medicine.A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.Diabetes and number of years of life lost with and without cardiovascular disease: a multi-state homogeneous semi-Markov model.
P2860
Q26779692-037F47C8-BDBE-4B2B-9E82-B70CC400E6B1Q26786366-2895D4CB-F92B-422D-8EF2-64311F49D597Q27309297-AE287088-98DC-490A-A8B2-003DA93BB49FQ30976026-D8235EB4-9E4D-44AA-9D4B-307207A51B35Q31064714-7DF9DDC5-78DB-4BD7-A18A-F538E55AD4D4Q33434899-B0C206C2-6F3E-4FF6-9E02-1314EA60DFB3Q35084155-AB0D0213-F4CA-4331-8CDA-8C1AFDEA9DD3Q35794099-776270C2-AD4D-4AE9-ACF2-9B419D70777CQ36020746-CF271640-D10F-4FE2-A6E3-A45EB7E6CDDDQ36546645-D2490863-BA9D-4C9E-BCE0-2E4330398FE4Q36588670-B5F24A88-E414-41F2-AC07-3CFB3AF073B8Q37708306-69BD0A73-CF82-40BF-9DB0-B343E6FD66A2Q38376705-728A4ADE-AEE9-4D8E-ACF8-A04A79C948F3Q38722045-33CF507A-D750-47E0-AAC2-DFC79EB05C19Q38790095-0791CF02-14AC-4A08-8010-E6F79B07A448Q38961574-FF21341E-8C19-46E1-994E-4679C59EABF6Q38978970-A95066AE-B23D-4590-9168-28E7773875A1Q39037219-CA93DF4C-4ABC-4D64-BC8F-3CCCEE858A7BQ39301205-730213CA-34A8-421C-A989-4CD83F70F4FFQ39584032-F6F9D123-4F6B-4F3A-9C1C-F0A7458A4296Q39647659-91786FD8-92E0-4B31-8806-6E3FDC85ECEBQ39953870-A3292BDB-4C23-436B-8CAF-83A666C07418Q40048382-07C479B6-8AF8-4F9D-BEA7-A870A3ACD4C1Q40484726-844CD418-20E1-43FE-A99B-2B0D26777681Q40858704-A2F4B04A-053D-4E02-A5CE-E227B5A913BCQ40906629-DF1FF4BE-EE5A-4F97-AC8D-2457F7E95F17Q41343301-84DC539F-743C-43A9-A94A-39EF782BCEF3Q42245812-D0606F85-3F05-4F60-97F4-0DF656A7020AQ42718198-BF57F8AB-2498-4DEF-88E0-AC52189C6046Q45304705-E7B30A2D-F16C-4E32-902D-128CA32FB379Q47115479-2A9517F6-6335-4E12-9778-6979A68AE63BQ47161614-E79DDA7E-208F-4843-86A3-D751CF08089DQ47190268-BBF8F0F9-306A-468D-BD4A-81A5683F0C88Q47360666-7902C403-FC99-4F9C-9476-7AF2B4C053E5Q47570953-893571E2-9517-4A65-A72C-0E3A33D038ADQ47693886-F29F21FE-9AE4-4C1D-B92F-D55605F1130AQ47916230-0DD0B232-556A-4B8E-B7FB-58A7898C3A25Q47935399-9B6A2471-BDE4-4202-8E8C-D2BF6F1A6EF0Q48226648-7DA692C9-8EBB-41D0-A463-24EA0332B9CEQ48312476-ACF47C9E-4DBE-4AEA-9640-75CDB58A3DB8
P2860
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Restricted mean survival time: ...... with a time-to-event outcome.
@ast
Restricted mean survival time: ...... with a time-to-event outcome.
@en
type
label
Restricted mean survival time: ...... with a time-to-event outcome.
@ast
Restricted mean survival time: ...... with a time-to-event outcome.
@en
prefLabel
Restricted mean survival time: ...... with a time-to-event outcome.
@ast
Restricted mean survival time: ...... with a time-to-event outcome.
@en
P2860
P356
P1476
Restricted mean survival time: ...... with a time-to-event outcome.
@en
P2093
Mahesh K B Parmar
P2860
P2888
P356
10.1186/1471-2288-13-152
P577
2013-12-07T00:00:00Z
P5875
P6179
1042461669